Newsroom

Lakewood-Amedex Advances Novel Bisphosphocin® Nu-8 Compound Based on Encouraging Pre-Clinical Results

SARASOTA, Fla., April 4, 2017 /PRNewswire/ -- Lakewood-Amedex Inc., a clinical stage pharmaceutical company developing novel anti-infectives, announced today that it is advancing...

04 April, 2017

Lakewood-Amedex Inc. Appoints Chief Medical Officer And Chief Scientific Officer To Enhance Drug Development And Clinical Trials Programs

SARASOTA, Fla., May 26, 2016 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has appointed Steve...

26 May, 2016

Lakewood-Amedex Announces Its Novel Bisphospocin® Class Of Antimicrobials Kills Multidrug Resistant-Tuberculosis (MDR-TB) Strains In Fifteen Minutes

SARASOTA, Fla., May 19, 2015 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that a recent series of...

19 May, 2015

Lakewood-Amedex Announces Expanded Research Collaboration With The University Of Jyvaskyla Following Promising Results Demonstrating Bisphosphocin™ Activity Against Borrelia Burgdorferi

SARASOTA, Fla., March 12, 2015 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has expanded upon...

12 March, 2015

Lakewood-Amedex Submits Investigational New Drug Application for Bisphosphocin™ Nu-3 for the Treatment of Diabetic Foot Infections

SARASOTA, Fla., Dec. 11, 2014 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced that the Company has submitted an...

11 December, 2014

Lakewood-Amedex Receives Notice Of Allowance From The United States Patent and Trademark Office (USPTO) For A New Patent Covering Its nanoRNA Gene-Silencing Technology

SARASOTA, Fla., Sept. 11, 2014 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that the United States Patent...

11 September, 2014

Lakewood-Amedex Raises $5.5 Million In Series C Preferred Stock Financing

SARASOTA, Fla., June 18, 2014 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has raised a...

18 June, 2014

Lakewood-Amedex Inc. Appoints Geoffrey F. Cox To Its Board Of Directors

SARASOTA, Fla., Jan. 8, 2014 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has elected Geoffrey...

08 January, 2014

Lakewood-Amedex Signs Strategic Advisory Agreement With H.C. Wainwright & Co.

SARASOTA, Fla., Oct. 9, 2013 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has entered into...

09 October, 2013

Lakewood-Amedex to Present Data on Bisphosphocin™ Nu-3 Bacteriacidal Effect on Bacteria Established in Biofilm at the ICAAC Conference

SARASOTA, Fla., Sept. 10, 2013 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that in vitro studies demonstrate...

10 September, 2013